Rituximab in bronchiolitis obliterans after haematopoietic stem cell transplantation

European Respiratory Journal

Volumn 38, Issue 2, 2011, Pages 470-472

  Lorillon, G ^a   Robin, M ^a   Meignin, V ^a   Ribaud, P ^a   Lescoeur, B ^b   Gossot, D ^c   Socie G ^a   Tazi, A ^a   Bergeron, A ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c INSTITUT MUTUALISTE MONTSOURIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CARBON DIOXIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; HLA ANTIGEN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MACROLIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; BRONCHIOLITIS OBLITERANS; CASE REPORT; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG DOSE INCREASE; DRUG PULSE THERAPY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HLA MATCHING; HODGKIN DISEASE; HUMAN; HYPERCAPNIA; LETTER; LUNG BIOPSY; LUNG FUNCTION TEST; MALE; MYELOABLATIVE CONDITIONING; PLEURECTOMY; PNEUMOTHORAX; PRIORITY JOURNAL; RESPIRATORY FAILURE; THORAX PAIN; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BRONCHIOLITIS OBLITERANS; BRONCHODILATOR AGENTS; FATAL OUTCOME; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MACROLIDES; MALE; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 80051498840     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00003711     Document Type: Letter

References (10)

1. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956. (Pubitemid 41754712)
2. Williams KM, Chien JW, Gladwin MT, et al. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009; 302: 306-314.
3. Dudek AZ, Mahaseth H, DeFor TE, et al. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003; 9: 657-666. (Pubitemid 38351785)
4. Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003; 9: 505-511. (Pubitemid 38351794)
5. Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, et al. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versushost disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant 2009; 15: 1005-1013.
6. Kim SJ, Lee JW, Jung CW, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective multicenter phase II study. Haematologica 2010; 95: 1935-1942.
7. Yoshihara S, Yanik G, Cooke KR, et al. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 749-759. (Pubitemid 46902446)
8. McGonagle D, Tan AL, Madden J, et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford) 2008; 47: 552-553.
9. Borie R, Debray MP, Laine C, et al. Rituximab therapy in autoimmune pulmonary alveolar proteinosis. Eur Respir J 2009; 33: 1503-1506.
10. Vandenbroucke E, Grutters JC, Altenburg J, et al. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int 2009; 29: 1499-1502.